| Market Cap | ₹121.53 CrPharmaceuticals |
|---|---|
| P/E Ratio | 29.54Sector: 43.58 |
| RSI | 53.0Neutral Zone |
| Deal value | ₹0.22 Cr |
| Share of market cap | 0.2% |
| Share of annual revenue | 0.2% |
Key highlights
- Allotment of 33,334 equity shares upon conversion of an equivalent number of convertible warrants
- Total transaction value for the conversion recorded at ₹22,25,044.50
- Promoter Priyanka Jaju's holding in the company increased from 2.00% to 2.15% post-allotment
- Equity share capital of the company expanded to 1,17,00,815 fully paid-up shares
- Company maintains a deadline of September 2027 for the conversion of remaining preferential warrants
Conversion Details and Shareholding Impact
Priyanka Jaju, a promoter and director of Godavari Drugs Ltd, completed the conversion of 33,334 convertible warrants on November 17, 2026. This conversion adds 33,334 new equity shares to her portfolio, bringing her total direct holding to 2,51,668 shares, which constitutes 2.15% of the updated equity base. The transaction was valued at ₹22.25 lakh, representing roughly 0.2% of the company's total market capitalization.
Following this allotment, the company's paid-up equity share capital increased from ₹10.91 crore to ₹11.70 crore, while the total diluted capital is pegged at ₹12.48 crore divided into 1.24 crore shares.
Financial Performance and Capacity Expansion
- The company reported a quarterly net profit of ₹0.96 crore for the period ended September 30, 2026
- Operating revenue for the latest quarter stood at ₹28.23 crore, marking a 5.92% year-on-year increase
- Operating profit margin improved significantly to 9.91% compared to 7.5% in the same period last year
- Godavari Drugs has deployed ₹44.12 crore for capacity expansion in API and anti-HIV intermediates
- The company secured a ₹34.00 crore working capital credit facility from ICICI Bank in October 2026
Official Disclosure on Warrant Conversion
I, Priyanka Jaju, Director of Godavari Drugs Limited inform that the Company had converted 33,334 convertible warrants to 33,334 Equity shares of the company. In this regard, I enclose herewith prescribed form u/r Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Market Context and Sector Comparison
Godavari Drugs currently operates with a market capitalization of ₹121.53 crore within the pharmaceuticals and biotechnology sector. The stock is trading at a trailing twelve-month P/E of 29.54, which sits below the industry average P/E of 43.62. While the company saw a slight year-on-year dip of 6.64% in annual net profit, the recent quarterly performance shows steady revenue growth.
The promoter group has been gradually consolidating their position, with the latest filings indicating a quarterly promoter holding increase of 4.31% leading up to this warrant conversion.
What to watch next
- Deadline for conversion of the remaining 15,73,375 preferential warrants in September 2027
- Operational commencement of the expanded API and anti-HIV manufacturing capacities
- Next quarterly financial results announcement expected in February 2027
| Share price | ₹120 |
|---|---|
| Market capitalisation | ₹121.53 Cr |
| Revenue (annual) | ₹105.81 Cr |
| Net profit (annual) | ₹4.09 Cr |
| Revenue (latest quarter) | ₹28.23 Cr+0.96% vs previous quarter |
| Net profit (latest quarter) | ₹0.96 Cr-13.70% vs previous quarter |
| P/E (TTM) | 29.54×Sector 43.58× |
| Promoter holding | 44.54%+4.31% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Godavari Drugs Ltd announcing the conversion of warrants into equity shares by a promoter director. Market figures from a third-party data provider.




